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Day 28 36% / 21% 64% / 36% 14% / 50% 93% / 86%
Day 42 57% / 21% 64% / 50% 29% / 43% 79% / 79%
Day 100 64% / 29% 71% / 50% 21% / 43% 79% / 50%
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SINGLE PRE-TRANSPLANT TREATMENT WITH GM-CSF-SECRETING
MYELOID LEUKEMIA CELL VACCINE COMBINED WITH AUTOLOGOUS-
BMT SIGNIFICANTLY IMPROVES SURVIVAL OF MYELOID LEUKEMIA
CHALLENGED MICE
Zilberberg, J., Friedman, T.M., Korngold, R. Hackensack University
Medical Center, Hackensack, NJ
A number of pre-clinical and recent clinical trials have demon-
strated the efficacy of tumor vaccines engineered to secrete GM-
CSF (GVAX) for the treatment of solid tumors and hematological
malignancies. We investigated the graft-versus-leukemia (GVL)
effects of a GM-CSF-secreting myeloid leukemia cell vaccine in
a murine bone marrow transplantation (BMT) model using the
MMB3.19 leukemia cell line, of C57BL/6 (B6) origin. Our approach
consisted of a recipient GVAX-preconditioning strategy, prior to
transplantation, that differed from current treatment designs in
that post-BMTdonor immune reconstitution was not required in or-
der to observe a significant GVL response, and a single GVAX injec-
tion, as opposed tomultiple treatments, was sufficient to significantly
improve survival of leukemia-challenged mice. B6 Mice received
a single subcutaneous preconditioning infusion of 2105 irradiated
GVAX tumor cells. Seven days later, mice were lethally irradiated
with 850 cGy and transplanted with 2106 anti-T cell-depleted B6
BM cells, alone or in combination with 4106 donor lymphocytes
(DL). On day 1 post-BMT, mice were challenged with 1105
MMB3.19 cells (i.p). Statistical comparisons using a non-parametric
log-rank test showed enhanced survival rate in the GVAX-precondi-
tioned group 70 days post-BMT (60% survival), compared to: DL
alone (10% survival, MST5 26 d, P5 0.01); GVAX given 1 day
post-BMT (20% survival, MST5 26.5 d, P5 0.01); and precondi-
tioning with irradiated tumor cells (30%, MST5 37.5 d,
P5 0.01). GVAX-preconditioned mice receiving no DL also had
significantly increased survival than DL alone (40% survival,
MST5 37.5 d, P5 0.02). These results indicate that a single pre-
transplant GVAX dose can significantly improve survival of
MMB3.19 challenged mice and suggests that after host irradiation,
immune cells exposed to GVAX remain capable of mediating signif-
icant GVL responses, even in the absence of DL.381
TREATMENT OF STEROID-REFRACTORY ACUTE GVHDWITH MESENCHY-
MAL STEM CELLS IMPROVES OUTCOMES IN PEDIATRIC PATIENTS;
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PLACEBO-CONTROLLED STUDY
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Successful treatment of steroid-refractory aGVHD (SR-GVHD)
following allogeneic hematopoietic cell transplantation remains
a significant challenge. Because of their immunomodulatory proper-
ties and safety profile, adult mesenchymal stem cells (MSCs) have
been proposed as a treatment for SR-GVHD. Intravenous allogeneic
MSC therapy (Prochymal) for SR-GVHDwas independently eval-
uated in the pediatric subset of a double-blind, placebo-controlled
study (Protocol 280).
Methods: Pediatric patients (\ 18 yrs) with grade B-D SR-GVHD
were randomized to receiveProchymal or placebo in addition to stan-
dard of care, including institutionally selected second line agent. Pa-
tients received 8 infusions of 2 106 cells/kg for 4 weeks (or volume
equivalent for placebo), with 4 more infusions weekly in the case of
a partial response (PR). The primary endpoint was durable complete
response (CR$ 28 days); secondary endpoints included incidence of
CR, PR and progression through 100 days, survival, and safety.
Results: Twenty-eight children were randomized to Prochymal
(50% male, 79% Caucasian) or placebo (71% male, 71% Cauca-
sian), with a median age of 7 yrs (range 1-15) and 10 years (range
1-18), respectively. The dominant transplant graft was cord blood(71% Prochymal, 57% placebo), with mostly unrelated donors
(93% vs 79%, respectively). The median duration of aGVHD prior
to enrollment was 20 days for Prochymal and 8 days for placebo
(p\0.05). At baseline, aGVHD grades B:C:D were 3:8:3 for
both arms. For Prochymal, organ involvement was 64% skin,
43% GI, and 36% liver. For placebo patients, organ involvement
was 57% skin, 79% GI, and 29% liver. Durable CR was 64% for
Prochymal and 43% for placebo. Prochymal improved rates of
CR and OR (Table). The median time to CR was 25 days vs 63
days. The 25% percentile of the survival function after study start
was 139 days for Prochymal and 50 days for placebo. The safety
data showed no infusional toxicity and no evidence of Prochymal
leading to ectopic tissue. There were no AEs leading to discontin-
uation of therapy.
Conclusion: In a SR-GVHD population in which 79% of patients
had grade C/D disease, the addition of Prochymal to standard of
care doubled 28 day CR rates and reduced progression by half. Re-
sponse at 28 days correlated with improved 100 day survival. Given
increased response rates and a well-tolerated safety profile, MSCs
appear to be a safe and effective therapy in the treatment of pediatric
patients with SR-GVHD.382
EFFECT OF CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4 (CTLA-4) HAPLO-
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CTLA-4 is a negative regulator for activated T cells and the asso-
ciation of CTLA-4 polymorphisms with autoimmune diseases has
been reported. The present study evaluated the effect of donor
CTLA-4 haplotype on the immune reaction after allogeneic hemato-
poietic stem cell transplantation (HSCT) such as graft-versus-host
disease (GVHD) and graft-versus-leukemia (GVL) effect. We ana-
lyzed 147 cases of Japanese HLA-matched sibling recipients and
their donors who had undergone allogeneicHSCT for the treatment
of hematological malignancies between 1987 and 2006 at the Na-
goya University Hospital and the Japanese Red Cross Nagoya First
Hospital. All recipients received T-cell-replete transplantation.
Cyclosporine and short-term methotrexate were used as GVHD
prophylaxis. Genotyping of three single nucleotide polymorphisms
(SNPs) in CTLA-4 (-318, +49, CT60) were performed by Taq-
man-PCR method and/or DNA sequencing method using genomic
DNA obtained from donor peripheral blood mononuclear cells
(PBMCs). Their haplotypes were determined based on the HapMap
database. Multivariate analyses were performed using Cox propor-
tional-hazard model. Age, conditioning, disease risk and graft source
were included as covariates. According to the HapMap database,
CTLA-4 haplotype (-318, +49, CT60) could be classified into three
types (C-G-G, C-A-A, T-A-G) in Japanese population. In this study,
the proportion of the haplotype C-G-G, C-A-A, and T-A-G were
59.5%, 30.6%, and 9.9%, respectively. Recipients who received
stem cells from a donor with the C-A-A haplotype showed signifi-
cantly lower disease relapse (HR: 0.53, 95%CI: 0.29-0.96,
